Well if you’re a medic and understand data then you’ll understand the problems inherent in comparing arms from different trials and drawing the sorts inferences that are being drawn. I’m not saying there’s anything wrong with LuPIN per se. Have Kinghorn explicitly stated LuPIN trial proves adding Nox drug to Lu is superior to Lu alone? Not that I’ve seen.
LuPIN abstract, page-16
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $42.51K | 418.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5591 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |